2019 HCPCS Codes > Q Codes >

Q2041

Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • 2019 Status Change: Change in long description of procedure or modifier code
  • Effective Date: 2018-04-01
  • Medicare Coverage Status: Carrier Judgement
  • BETOS Classification: Other drugs

Medicare has not assigned a fee schedule for this code

Q2040       Q2042